<DOC>
	<DOCNO>NCT02431325</DOCNO>
	<brief_summary>The purpose research study determine whether teduglutide repair `` leaky '' gut , decrease inflammation , prevent treat plaque , build-up fat material blood vessel heart , people HIV . HIV disease link inflammatory change leakiness gut . These change condition may increase risk develop heart blood vessel disease . The investigator believe teduglutide help repair gut barrier people HIV , lead decrease inflammation plaque blood vessel heart .</brief_summary>
	<brief_title>A Study Gut Barrier Blood Vessel Inflammation Individuals With Without HIV</brief_title>
	<detailed_description>As people HIV gain access combination antiretroviral therapy ( cART ) , cardiovascular disease become increasingly prevalent significant cause mortality . Activation innate immune system may stimulate inflammatory mechanism atherosclerosis development . Loss gastrointestinal ( GI ) mucosal epithelial integrity loss CD4+ T-lymphocytes intestinal lamina propria occur HIV-infected patient fully restore cART . Translocation microbial product intestinal lumen systemic circulation demonstrate increased HIV-infected patient investigator hypothesize key driver monocyte macrophage activation . In turn , pro-inflammatory monocyte macrophage induce atherosclerotic disease development . The purpose research study determine effect glucagon-like peptide-2 analog , teduglutide , intestinal epithelial integrity , microbial translocation across gut lumen , marker innate immune system activation include monocyte transcriptome , bone , arterial inflammation , atherosclerosis 6-month randomize , double-blind placebo-controlled proof concept trial HIV-infected individual .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<criteria>1 . Men woman age 2165 previously diagnose HIV disease 2 . Stable antiretroviral therapy ( ART ) define change ART regimen &gt; 6 month 3 . HIV viral load &lt; 200 copies/mL 4 . To eligible colonoscopy procedure , laboratory value meet follow criterion : 1 . Hemoglobin &gt; 9.0 g/dL 2 . Absolute neutrophil count ≥ 1000/mm3 3 . Platelet count ≥ 100,000/mm3 4 . Prothrombin time ( PT ) &lt; 1.2 x upper limit normal ( ULN ) 5 . Partial thromboplastin time ( PTT ) &lt; 1.5 x ULN 4 . Ability willingness give write informed consent comply study requirement 1 . History clinically significant gastrointestinal disease include limited : colon cancer , intestinal obstruction , ulcerative colitis , Crohn 's disease , history C. difficile within past 3 month 2 . Firstdegree relative history colon cancer 3 . Active gall bladder , biliary pancreatic disease 4 . Female subject pregnant , nurse less 8 week post partum . 5 . Use immunomodulatory agent within 30 day prior study enrollment 6 . History intolerance , sensitivity , allergy anaphylaxis benzodiazepine narcotic use colonoscopy upper endoscopy procedure 7 . Contraindication betablocker ( include moderate severe asthma heart block ) nitroglycerin use drug give part standard cardiac CT protocol . Previous allergic reaction beta blocker nitroglycerin . 8 . Patients previous allergic reaction iodinecontaining contrast medium 9 . Renal disease creatinine &gt; 1.5 mg/dL ( contrast administer CT angiography heart ) 10 . History require antibiotic prophylaxis invasive procedure 11 . History myocardial infarction , decompensated cirrhosis , condition opinion investigator compromise ability participate study 12 . Currently take anticoagulant include limited : heparin ( HepLock , HepPak ) , HepPak CVC , Heparin Lock Flush ) , warfarin ( Coumadin ) , tinzaparin ( Innohep ) , enoxaparin ( Lovenox ) , danaparoid ( Orgaran ) , dalteparin ( Fragmin ) , clopidogrel ( Plavix ) , prophylactic aspirin , regular NSAID use 13 . Subject take following medication : statin , systemic steroid ( inhale nasal steroid therapy permit ) , interleukins , systemic interferon ( e.g . local injection interferon alpha treatment HPV permit ) , systemic chemotherapy include oral chemotherapeutic agent , methotrexate , octreotide , growth hormone , antiarrhythmic include digoxin , antiepileptic , immunosuppressant , vancomycin , rifampin , aminoglycosides , clonidine , prazosin , lithium ritonavirboosted lopinavir ( Kaletra ) . 14 . Subject two endoscopy procedure ( sigmoidoscopy , upper endoscopy colonoscopy ) within past 12 month clinical purpose research study . 15 . Body weight great 300 lb due CT scanner table limitation 16 . Active illicit drug use 17 . Patients report significant radiation exposure course year prior randomization . Significant exposure define : 1 . More 2 percutaneous coronary intervention ( PCI ) within 12 month randomization 2 . More 2 myocardial perfusion study within past 12 month 3 . More 2 CT angiogram within past 12 month 4 . Any subject history radiation therapy 18 . Patients already schedule consider procedure treatment 1. require significant radiation exposure ( e.g. , radiation therapy , PCI , catheter 2. ablation arrhythmia ) within 12 month randomization 19 . History malignancy 20 . Prior recipient HIV vaccine</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Microbial Translocation</keyword>
	<keyword>Teduglutide</keyword>
	<keyword>Gastrointestinal Permeability</keyword>
	<keyword>Inflammation</keyword>
</DOC>